INCORTA
8.6.2021 17:14:04 CEST | Business Wire | Press release
Incorta , the Direct Data Platform™, today announced a multi-year partnership with MDSap , a sub-holding of Midis Group, a global leader in redistributing and reselling, to expand its go-to-market in the Middle East, Turkey, and Eastern Europe and address the region’s growing need for modern analytics and business intelligence. The partnership will provide MDSap’s 400 global enterprise customers with a fast and scalable data analytics solution, bringing Incorta’s Direct Data Platform to key regions such as the Middle East, North Africa, Turkey and Eastern Europe.
The COVID-19 pandemic spurred a rapid increase in the need for advanced technology, and Incorta’s presence in the Middle East is expected to grow by more than 100% this year – a market valued at $11 billion in 2020 and expected to reach $28 billion by 2026. The partnership will help replace outdated, legacy solutions, bringing modern data analytics to new and existing customers at unprecedented speed and scale.
“We’re thrilled to partner with Incorta to bring their state-of-the-art data analytics solution to our enterprise customers,” said Tony Achkar, group managing director of MDSap. “As the Middle East, Turkey and Eastern Europe regions continue to experience rapid digitization, our customers need a modern solution to help them keep up with today’s pace of business. Incorta is allowing them to analyze their data at a level of speed and scale they’ve never seen before.”
As SAP’s gold partner, MDSap leverages SAP technology and other solution providers to help businesses run smoothly and efficiently. Making smart, data-informed decisions is a key part of operating a business, as MDSap customers require the ability to quickly analyze, ingest and then act on their data in order to gain crucial insights about their business. Incorta’s Direct Data Platform will enable users to analyze massive sets of data at lightning speed, allowing them to maximize the full value of their data.
“The Middle East presents exciting opportunities for digital transformation and growth, especially in the data analytics market,” said Incorta CEO Scott Jones. “We are proud to be partnering with MDSap to help more companies in the region innovate and thrive with tools for making the most of their business data.”
The Incorta and MDSap integration is available now.
For more information, visit https://www.incorta.com/partners/mdsap .
About Incorta
Incorta is the only unified data analytics platform powered by Direct Data Mapping™. Purpose-built to help companies stay ahead of the accelerating rate, volume, and complexity of modern enterprise data, the platform delivers unmatched speed and visibility. Incorta is built with open standards and integrates with cloud-friendly tools and platforms, making it easy to consolidate data in the cloud and extract meaningful insights. By making any data source continuously available for analytics, the platform helps business leaders, business teams, and data scientists make more accurate, timely and transparent decisions with faster access to richer data sets. Backed by GV (formerly Google Ventures), Kleiner Perkins, M12 (formerly Microsoft Ventures), Telstra Ventures and Sorenson Capital, Incorta powers analytics for some of the most valuable brands in the world, including Broadcom, Credit Suisse and Shutterfly. To learn more and try it for yourself, visit www.incorta.com .
About MDSap
MDSap, a gold partner of SAP and expert in SAP’s banking solutions, has over 25 years of in-depth experiences helping customers manage, integrate, analyse and mobilize business mission critical data across the enterprise. The company has an exceptional track record providing turnkey IT solutions across the Middle East, Turkey & Central Eastern Europe to over 400 enterprise customers and government entities. MDSap is part of the Midis Group and is a member of EPM International and currently operates 10 offices across the Middle East, Turkey and Central Eastern Europe.
For more information, visit https://www.mdsaptech.com/en/ .
About Midis Group
With more than 5,000 professionals, representing the top 100 global IT vendors, and a solid 50-year track record of performance and reliability, the Midis Group is an international organization of over 170 companies across Europe, the Middle East & Africa. The group is known for its advanced offering of managed IT services and consultancy, system integration, cloud and data center capabilities and infrastructure, software and hardware solutions, as well as technology distribution and retail. It was named in 2006 as one of the World Economic Forum’s initial 100 Global Growth Companies. The group focuses on providing the best in services, with integrity, to vendors, partners, and customers across the destinations it serves. For more information, visit: www.midisgroup.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005870/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom